Tulobuterol is a long-acting β2-adrenergic receptor agonist with bronchodilatory, anti-inflammatory, and antiviral activities; it reduces RV14 RNA levels, suppresses RV14 infection-induced secretion of IL-1β, IL-6, and IL-8, decreases sICAM-1 concentrations, inhibits acidic endosome formation, and attenuates NF-κB activation (p50, p65, c-Rel) in human tracheal epithelial cells; in vivo, it maintains diaphragm muscle contractility during endotoxin-induced dysfunction via transdermal administration.